Neuroscience analysis technology specialist Ixico has been selected by an unnamed, “leading” global pharmaceutical company and new client, it announced on Friday, to provide MRI imaging services for an early-phase clinical trial in multiple system atrophy.
The AIM-traded firm said it had signed a start-up agreement with the client, which was expected to extend to a contract value of about £0.6m early in 2023.

It said the trial was expected to last for two years.

“Since its inception, Ixico has built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders across the entire drug development lifecycle, from phase one through to commercialisation,” the board said in its statement.

At 1430 GMT, shares in Ixico were up 5.49% at 26.9p.

Reporting by Josh White for

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!